Hoth Therapeutics Wins Japanese Patent for HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics, Inc., a biopharmaceutical firm focused on developing cutting-edge therapies, announced a significant milestone with the acquisition of a new patent in Japan. The Japan Patent Office granted the company Patent No. 7677628 on May 7, 2025, providing exclusive rights for its HT-KIT platform until August 27, 2039. This development is a crucial step for Hoth Therapeutics, as it secures long-term commercial exclusivity in one of the world's most important pharmaceutical markets.

The patented technology involves the use of splice-switching oligonucleotides (SSOs) to target and alter the expression of the KIT gene in mast cells. This innovative approach aims to induce apoptosis in these cells, which are involved in various diseases, ranging from chronic inflammatory conditions like hives to certain rare cancers. By specifically disrupting the KIT gene, the HT-KIT platform holds promise for treating these mast cell-related conditions, potentially offering new solutions for patients who have limited treatment options.

Robb Knie, CEO of Hoth Therapeutics, emphasized the importance of securing intellectual property rights in Japan, highlighting the strategic value of the HT-KIT platform. He noted the potential for licensing opportunities across Asia, a region where the company aims to expand its reach and collaborate with strategic partners for co-development and commercialization.

The newly awarded patent protects not only the innovative SSOs technique but also positions Hoth Therapeutics to pursue orphan drug indications. Orphan drugs target rare diseases and often benefit from expedited regulatory pathways, which can accelerate the time to market. This strategic positioning is a testament to the company's commitment to advancing novel treatments that address significant unmet medical needs.

HT-KIT is one of several promising platforms under development at Hoth Therapeutics. The company remains focused on forging partnerships with global entities, particularly throughout Asia, to leverage co-development and market expansion opportunities. This proactive approach aligns with Hoth's broader goal to enhance patient care by bringing groundbreaking therapies from the research phase to clinical trials and eventually to the patients who need them.

Hoth Therapeutics is at the forefront of pharmaceutical innovation, dedicated to improving patient outcomes through the development of transformative treatments. By collaborating with scientists, clinicians, and industry experts, the company is actively engaged in identifying and advancing therapeutic candidates that could lead to significant breakthroughs in the field.

This patent acquisition in Japan is a pivotal achievement for Hoth Therapeutics, reinforcing its strategic direction and commitment to addressing complex medical conditions through novel therapeutic platforms. With protection in place until 2039, the company is well-positioned to explore and capitalize on new opportunities in the pharmaceutical market, furthering its mission to enhance the quality of life for patients worldwide.